Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$21.70M+8225.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Cary G. Vance
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 226
- Beta
- 2.02
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -11.39
Financials
Revenue
$21.70M+8225.1%Net Income
$-7.66MEBITDA
$-4.82MFree Cash Flow
$-3.60MEPS (diluted)
$-0.25Shares Outstanding (diluted)
30.75M+432.3%Operating Expenses
$24.62MCash & Debt
$11.13MRevenue by Segment (annual)
$731.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $71.61M | $-48.59M | $-1.74 |
| 2024 | $64.25M | $-61.84M | $-2.39 |
| 2023 | $50.14M | $-35.38M | $-1.40 |
| 2022 | $34.42M | $-26.66M | $-1.07 |
| 2021 | $33.02M | $-25.14M | $-1.03 |
| 2020 | $29.23M | $-26.58M | $-1.17 |
| 2019 | $14.26M | $-42.03M | $-2.07 |
| 2018 | $7.83M | $-35.90M | $-1.60 |
| 2017 | $1.70M | $-23.37M | $-2.50 |
| 2016 | $1.54M | $-15.03M | $-2.25 |
| 2015 | $1.34M | $-13.77M | $-2.76 |
| 2014 | $997.1K | $-10.34M | $-2.93 |
| 2013 | $2.86M | $-5.48M | $-1.68 |
| 2012 | $3.04M | $-8.75M | $-2.91 |
Valuation
RCELhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (12)
- Newsdefenseworld.net·11d ago·Neutral
NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL NewEdge Advisors LLC grew its position in Avita Medical Inc. (NASDAQ: RCEL) by 71.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 148,931 shares of the company's stock after purchasing an additional 62,046 shares during the quarter. NewEdge Advisors LLC owned
View source ↗ - Newsseekingalpha.com·19d ago·Positive
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·35d ago·Positive
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·42d ago·Positive
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy? Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsseekingalpha.com·43d ago·Neutral
AVITA Medical: Favorable Reimbursements For Skin Wound Care AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
View source ↗ - Newsmarketbeat.com·48d ago·Negative
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·49d ago·Negative
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
View source ↗ - Newsmarketbeat.com·50d ago·Neutral
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18% Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
View source ↗ - Newsmarketbeat.com·50d ago·Neutral
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds Avita Medical NASDAQ: RCEL expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.24 per share
Typical surprise -7.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.25 vs $-0.29beat
- Thu, May 14$-0.35 vs $-0.35beat
- Thu, Feb 12$-0.38 vs $-0.36miss
- Thu, Nov 6$-0.46 vs $-0.43miss
- Thu, Aug 7$-0.38 vs $-0.26miss
- Thu, May 8$-0.53 vs $-0.39miss
Estimates and results for RCEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RCEL officers and directors.
- Bought
- $613k
- Sold
- $148k
33 trades
4 trades
- O'toole David Dbought
- Woody Joseph Fralinbought
- Woody Joseph Fralinbought
- Woody Joseph Fralinbought
- Woody Joseph Fralinbought
- Woody Joseph Fralinbought
- O'toole David Dbought
- O'toole David Dbought
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RCEL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.